Reported GAAP EPS of -$0.32 down -14.29% YoY
Bullish
Skye Bioscience's nimacimab demonstrated incremental weight-loss benefits and a favorable tolerability profile, while the company progressed its CBeyond study and engaged Lilly Catalyze360 for Phase 2b trial design.
Bearish
Skye Bioscience's cash runway is limited, excluding future Phase 2b clinical and manufacturing costs, while net loss increased to $12.5M in Q1 2026, reflecting higher R&D expenses and operational risks.